1st COLDA – presentations


Thursday 13 September - Day 1

 Introduction to Viral Hepatitis and Liver Disease
Chairs: Mark Nelson & Manal El-Sayed
 Clinical spectrum of liver disease in Africa
Wendy Spearman, MBChB, Mmed, PhD, University of Cape Town, South Africa
 The ABC of viral hepatitis
Mark Thursz, MRCP, Imperial College, St Mary's Hospital, UK
 Essential diagnostic tools for viral hepatitis
Elijah Songok, MD, MSc, KEMRI, Kenya
(Not available)
 Session 1: Situation of Liver Disease in Africa
Chairs: Mark Nelson & Reena Shah
 Burden of Liver Disease in North Africa
Ayman Yosry, Cairo University, Egypt
 The global challenge of viral hepatitis
Lesi Olufunmilayo, FWACP, FMCP, University of Lagos, Nigeria
 Session 2: HIV-Hepatitis Coinfections
Chair: Kosh Agarwal & Edford Sinkala
 The dangers of not treating-modelling the viral hepatitis epidemic in Africa
Shevanthi Nayagam, MBBS, Imperial College, UK
(Not available)
 Hepatitis D - a forgotten foe?
Richard Njouom, PhD, Centre Pasteur, Cameroon
 Abstract driven presentations 
 Hepatitis B stigma by association with HIV in Zambia
Michael Vinikoor
 Prevalence estimates of chronic hepatitis B virus infection: a comparative study of four sources and implications for burden assessment in sub-Saharan Africa
Nora Schmit
 Epidemiology of hepatitis B and evaluation of vaccine efficacy in a census-based community serosurvey of Ndirande township in Blantyre, Malawi
Alexander Stockdale

Friday 14 September - Day 2

 Session 3: Hepatitis B
Chair: Elyah Songok & John Rwegasha
 Whats new in hepatitis B (treatment and monitoring)
Mark Sonderup, B Pharm MBChB FCP(SA) MMED, University of Cape Town, South Africa
(Not available)
 MTC transmission of HBV
Christian Tzeuton, MD Douala Medical School / Société Camerounaise de Gastro-Enterologie, Cameroon
 Abstract driven presentations 
 Hepatitis B screening and prevention integration into ante-natal care and delivery services in an urban cohort in Mozambique
Natalia Tamayo Antabak
 Population-based evaluation of hepatitis B markers and criteria for antiviral therapy in Lusaka Province, Zambia
Michael Vinikoor
 Treatment of chronic hepatitis B in sub-Saharan Africa: 3-year results of a pilot program in Ethiopia
Asgeir Johannessen
 Characterization of Hepatitis B Virus (HBV) Among Liver Patients in Kenya
Missiani Ochwoto
 Session 4: Hepatitis C
Chair: Manal El-Sayed & Richard Njouom
 How to treat HCV in a resource limited setting
Ayman Yosry, Cairo University, Egypt
 Abstract driven presentations 
 Prevalence of HBV and HCV infections in screened people in Rwanda during WHD 2017 campaign
Jean Damascene Makuza
 HCV diagnosis and direct-acting antiviral agents -based treatment for HIV/HCV co-infected patients in a primary care setting in Maputo, Mozambique
Natalia Tamayo Antabak
 Ledipasvir/Sofosbuvir for Treatment of Hepatitis C Virus Infection in Rwanda: Results from the SHARED Trial
Emmanuel Musabeyezu
 Session 5: Liver Disease in Special Population
Chair: Wendy Spearman & Mark Sonderop
 Viral hepatitis in paediatrics (B and C)
Manal El-Sayed, MD, Ain Shams University, Cairo, Egypt
 Other special populations (PWID)
John Rwegasha, MBChB, M.MED, FRCP, MSc - Muhimbili National Hospital, Tanzania
 Session 6: Future issues in liver disease in Africa
Chair: Francesco Marinucci & Shevanthi Nayagam
 Alcoholic liver disease
Kosh Agarwal, MD, King’s College Hospital, UK
 Johannessen, Asgeir 2018Drug-induced liver disease: khat and other weeds
Asgeir Johannessen, Oslo University Hospital, Norway
 Fatty Liver disease
Mark Thursz, MRCP, Imperial College, St Mary's Hospital, UK

Saturday 15 September - Day 3

 Session 7: Other infectious liver disease
Chair: Lesi Olufunmilayo & Mark Thursz
 Parasitic infections (Schistosomiasis infection, Liver flukes)
Edford Sinkala, BScHB, MBChB, MMed, PhD, FRCP, University Teaching Hospital, Lusaka, Zambia
 Abstract driven presentations
 Point-of-care testing for hepatitis B virus infection in a community-based occupational health cohort in the Western Cape Province, South Africa
Nafiisah Chotun
 Mother-to-child transmission of hepatitis B virus in Windhoek, Namibia: transmission dynamics and prevention
Cynthia Tamandjou
(Not available)
 Session 8: Clinical management of End-stage Liver Disease
Chairs: Gamal Esmat & Johannessen Asgeir
 Management of end-stage Liver Disease in Resource Limited Settings
Mark Sonderup, University of Cape Town, South Africa
 Management of Hepatocellular Carcinoma in Africa
Wendy Spearman, MBChB, Mmed, PhD, University of Cape Town, South Africa
 Abstract driven presentations
 Large-scale discovery and validation of blood and urinary discriminant metabolites as potential biomarkers for the diagnosis hepatocellular carcinoma in West Africa 
Mei Ran Abellona U
 The establishment of hepatitis B care and treatment clinics in the United Republic of Tanzania: A demonstration project following WHO guidelines
John Rwegasha
 Session 9: Liver Disease - Public health issues
Chair: Reena Shah & Ayman Yosry
 New diagnostics to improve diagnosis of liver disease
Francesco Marinucci, FIND, Italy
 Improving access to treatment in Resource Limited Settings
Manal El-Sayed, MD, Ain Shams University, Cairo, Egypt
(Not available)
 Jessica Hicks 2018 120x160NOhep Visionaries in Africa: Medical professionals leading the way towards hepatitis elimination
Jessica Hicks, World Hepatitis Alliance